Jan 04, 2024 4:01 pm EST Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Dec 20, 2023 4:01 pm EST Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories
Dec 11, 2023 12:00 pm EST Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting
Dec 01, 2023 4:01 pm EST Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 29, 2023 6:05 pm EST Atara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023
Nov 22, 2023 4:01 pm EST Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conference
Nov 08, 2023 5:35 pm EST Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis
Nov 01, 2023 8:30 am EDT Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results
Oct 06, 2023 4:01 pm EDT Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)